- Senseonics Holdings (SENS, Financial) will host an analyst event on June 21, 2025, at the Marriot Marquis Chicago.
- The event will showcase the FDA-approved Eversense 365 Continuous Glucose Monitoring system.
- Key discussions will include the commercial launch and future technology developments in diabetes care.
Senseonics Holdings, Inc. (SENS), a leader in medical technology for diabetes care, has announced an upcoming analyst event scheduled for June 21, 2025, at 8:00am CT. The event will take place at the Marriot Marquis Chicago, coinciding with the American Diabetes Association 85th Scientific Sessions (ADA 2025). Attendees can join both in-person and virtually.
The focus of the event will be on the Eversense 365 Continuous Glucose Monitoring (CGM) system, which has received approval from the U.S. Food and Drug Administration (FDA) for use in diabetes patients aged 18 and older. This system represents an advance in long-term, implantable glucose management technology, designed to improve the quality of life for those living with diabetes.
Key speakers at the event include company management, Brian Hansen from Ascencia Diabetes Care, who will discuss the commercial launch of Eversense 365, and Gary Graf from Cotton-O'Neil Diabetes and Endocrinology Center, who will share insights on the system’s user experience and insertion procedures. Additionally, discussions will cover Senseonics’ partnership with Sequel to integrate the twiist automated insulin delivery pump, along with future developments in implantable CGM technology.
The event will conclude with a live question and answer session, providing an opportunity for attendees to engage with the speakers and company representatives directly.
